Search Results - "Kinon, Bruce J."

The Group of Treatment Resistant Schizophrenias. Heterogeneity in Treatment Resistant Schizophrenia (TRS) by Kinon, Bruce J

“…Schizophrenia is composed of a heterogeneous group of patient segments. Our current notion of the heterogeneity in schizophrenia is based on patients…”
Get full text

Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia by Kinon, Bruce J, Millen, Brian A, Zhang, Lu, McKinzie, David L

“…Abstract Background Accumulating evidence indicates that glutamatergic tone in schizophrenia may vary as a function of illness duration or medication history…”
Get full text

A predictor model of treatment resistance in schizophrenia using data from electronic health records by Kadra-Scalzo, Giouliana, Fonseca de Freitas, Daniela, Agbedjro, Deborah, Francis, Emma, Ridler, Isobel, Pritchard, Megan, Shetty, Hitesh, Segev, Aviv, Casetta, Cecilia, Smart, Sophie E, Morris, Anna, Downs, Johnny, Christensen, Søren Rahn, Bak, Nikolaj, Kinon, Bruce J, Stahl, Daniel, Hayes, Richard D, MacCabe, James H

“…To develop a prognostic tool of treatment resistant schizophrenia (TRS) in a large and diverse clinical cohort, with comprehensive coverage of patients using…”
Get full text

Improving Translational Relevance in Preclinical Psychopharmacology (iTRIPP) by Bailey, Sarah J, Bast, Tobias, Chaby, Lauren, Kinon, Bruce J, Harte, Michael K, Mead, Sally, Moloney, Rachel D, Ragan, Ian, Stanford, S Clare, Tricklebank, Mark D, Zervas, Mark, Ajram, Laura A

“…Animal models are important in preclinical psychopharmacology to study mechanisms and potential treatments for psychiatric disorders. A working group of 14…”
Get full text

Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia by KINON, Bruce J, LEI CHEN, ASCHER-SVANUM, Haya, STAUFFER, Virginia L, KOLLACK-WALKER, Sara, WEI ZHOU, KAPUR, Shitij, KANE, John M

“…Our objective was to prospectively assess whether early (ie, 2 weeks) response to an antipsychotic predicts later (12-week) response and whether 'switching'…”
Get full text

Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine by Fonseca de Freitas, Daniela, Kadra-Scalzo, Giouliana, Agbedjro, Deborah, Francis, Emma, Ridler, Isobel, Pritchard, Megan, Shetty, Hitesh, Segev, Aviv, Casetta, Cecilia, Smart, Sophie E, Downs, Johnny, Christensen, Søren Rahn, Bak, Nikolaj, Kinon, Bruce J, Stahl, Daniel, MacCabe, James H, Hayes, Richard D

“…Background: A proportion of people with treatment-resistant schizophrenia fail to show improvement on clozapine treatment. Knowledge of the sociodemographic…”
Get full text

Clinical correlates of early onset antipsychotic treatment resistance by Fonseca de Freitas, Daniela, Agbedjro, Deborah, Kadra-Scalzo, Giouliana, Francis, Emma, Ridler, Isobel, Pritchard, Megan, Shetty, Hitesh, Segev, Aviv, Casetta, Cecilia, Smart, Sophie E., Morris, Anna, Downs, Johnny, Christensen, Søren Rahn, Bak, Nikolaj, Kinon, Bruce J., Stahl, Daniel, Hayes, Richard D., MacCabe, James H.

“…Background: There is evidence of heterogeneity within treatment-resistant schizophrenia (TRS), with some people not responding to antipsychotic treatment from…”
Get full text

Dynamic ElecTronic hEalth reCord deTection (DETECT) of individuals at risk of a first episode of psychosis: a case-control development and validation study by Raket, Lars Lau, Jaskolowski, Jörn, Kinon, Bruce J, Brasen, Jens Christian, Jönsson, Linus, Wehnert, Allan, Fusar-Poli, Paolo

“…Many individuals who will experience a first episode of psychosis (FEP) are not detected before occurrence, limiting the effect of preventive interventions…”
Get full text

Transdiagnostic individualized clinically-based risk calculator for the automatic detection of individuals at-risk and the prediction of psychosis: external replication in 2,430,333 US patients by Oliver, Dominic, Wong, Chiew Meng Johnny, Bøg, Martin, Jönsson, Linus, Kinon, Bruce J., Wehnert, Allan, Jørgensen, Kristian Tore, Irving, Jessica, Stahl, Daniel, McGuire, Philip, Raket, Lars Lau, Fusar-Poli, Paolo

“…The real-world impact of psychosis prevention is reliant on effective strategies for identifying individuals at risk. A transdiagnostic, individualized,…”
Get full text

A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naïve schizophrenia patients based on multimodal neuropsychiatric data by Ambrosen, Karen S., Skjerbæk, Martin W., Foldager, Jonathan, Axelsen, Martin C., Bak, Nikolaj, Arvastson, Lars, Christensen, Søren R., Johansen, Louise B., Raghava, Jayachandra M., Oranje, Bob, Rostrup, Egill, Nielsen, Mette Ø., Osler, Merete, Fagerlund, Birgitte, Pantelis, Christos, Kinon, Bruce J., Glenthøj, Birte Y., Hansen, Lars K., Ebdrup, Bjørn H.

“…The reproducibility of machine-learning analyses in computational psychiatry is a growing concern. In a multimodal neuropsychiatric dataset of…”
Get full text

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs by Liu-Seifert, Hong, Adams, David H, Kinon, Bruce J

“…Stopping antipsychotic treatment can interrupt improvement and exacerbate the illness. The reasons for discontinuing treatment during controlled clinical…”
Get full text

Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison by Kinon, Bruce J., Millen, Brian A., Zhang, Lu, Adams, David H., Gomez, Juan-Carlos

“…We tested the hypothesis that long-term treatment with pomaglumetad methionil would demonstrate significantly less weight gain than aripiprazole in patients…”
Get full text

Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study by Haynes, Virginia S, Zhu, Baojin, Stauffer, Virginia L, Kinon, Bruce J, Stensland, Michael D, Xu, Lei, Ascher-Svanum, Haya

“…Little is known about the long-term outcomes for patients with schizophrenia who fail to achieve symptomatic remission. This post-hoc analysis of a 3-year…”
Get full text

A Phase 2, Placebo-Controlled Study of the Opioid Receptor Antagonist LY2196044 for the Treatment of Alcohol Dependence by Wong, Conrad J., Witcher, Jennifer, Mallinckrodt, Craig, Dean, Robert A., Anton, Raymond F., Chen, Yunfei, Fijal, Bonnie A., Ouyang, Haojun, Dharia, Sweta, Sundseth, Scott S., Schuh, Kory J., Kinon, Bruce J.

“…Background Endogenous opioid‐mediated reward pathways may play a role in the development and maintenance of alcohol dependence. This study tested whether…”
Get full text

Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials by Kinon, Bruce J, Gilmore, Julie A, Liu, Hong, Halbreich, Uriel M

“…Background: Atypical antipsychotic drugs for the treatment of schizophrenia provide effective treatment of psychotic symptoms with a safety profile superior to…”
Get full text

Predictors of switching antipsychotic medications in the treatment of schizophrenia by Nyhuis, Allen W, Faries, Douglas E, Ascher-Svanum, Haya, Stauffer, Virginia L, Kinon, Bruce J

“…To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the…”
Get full text

Rationale for Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia by Kinon, Bruce J, Leucht, Stefan, Tamminga, Carol, Breier, Alan, Marcus, Ronald, Paul, Steven M

“…Schizophrenia is a complex syndrome with taxing symptoms and for which treatment challenges remain. Current dopamine D receptor-blocking antipsychotics have…”
Get full text

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia by Ascher-Svanum, Haya, Nyhuis, Allen W, Faries, Douglas E, Ball, Daniel E, Kinon, Bruce J

“…Individuals with schizophrenia may have a higher risk of encounters with the criminal justice system than the general population, but there are limited data on…”
Get full text

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia by Faries, Douglas E, Ascher-Svanum, Haya, Nyhuis, Allen W, Kinon, Bruce J

“…Switching between antipsychotic medications is common in the treatment of schizophrenia. However, data on clinical and economic outcomes from antipsychotic…”
Get full text

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia by Ascher-Svanum, Haya, Stensland, Michael, Zhao, Zhongyun, Kinon, Bruce J

“…Previous research indicated that women are more vulnerable than men to adverse psychological consequences of weight gain. Other research has suggested that…”
Get full text